journal article·2025-12Open access

Free‐Form Microfluidic Microneedle Array Patches

Ian A. Coates, Madison M. Driskill, Netra U. Rajesh, Gabriel Lipkowitz, Dan Ilyn, Yue Xu, Maria T. Dulay, Gunilla B. Jacobson, John R. Tumbleston, Jillian L. Perry, Shaomin Tian, Joseph M. DeSimone

Advanced Functional Materials· Volume 35· Issue 52

Abstract

Abstract Personalized biomedical devices, such as microneedle array patches (MAPs), represent a promising platform for transdermal drug delivery, offering a safe, minimally invasive, and user‐friendly alternative to traditional hypodermic injections. However, broader adoption is constrained by limitations in payload capacity, delivery versatility, and scalable manufacturing. To address these challenges, microfluidic channel architectures are integrated with MAP technology to enable the delivery of a range of payload formats including liquids and solid‐state cargos. Using injection continuous liquid interface production (iCLIP), an additive manufacturing technique capable of producing high‐resolution structures, complex microfluidic MAPs are fabricated with precise and reproducible geometries. The microneedles feature a side‐opening bore that reduces the risk of clogging during insertion and supports consistent transdermal fluid delivery. This platform allows for the reliable administration of multiple distinct payloads, combinational mixing, and point‐of‐care reconstitution of solid formulations.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Dermatology and Skin Diseases · Ocular Surface and Contact Lens

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemical Engineering Stanford University Stanford CA 94305 USA

Department of Bioengineering Stanford University Stanford CA 94305 USA

Department of Mechanical Engineering Stanford University Stanford CA 94305 USA

Department of Radiology Stanford University Stanford CA 94305 USA

Center for Nanotechnology in Drug Delivery and Division of Pharmacoengineering and Molecular Pharmaceutics Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill NC 27599 USA

Department of Microbiology and Immunology University of North Carolina at Chapel Hill Chapel Hill NC 27599 USA

Funding

Bill and Melinda Gates Foundation

References (66)

Show source-provided references
1. 10.1021/jacsau.2c0043210.1021/jacsau.2c00432 ↗
2. 10.1038/nbt.150410.1038/nbt.1504 ↗
3. 10.1016/j.vaccine.2014.01.07610.1016/j.vaccine.2014.01.076 ↗
4. 10.1021/js98004210.1021/js980042 ↗
5. 10.3390/polym1316281510.3390/polym13162815 ↗
6. 10.1038/nm.218210.1038/nm.2182 ↗
7. 10.1038/s41587‐023‐01774‐z10.1038/s41587‐023‐01774‐z ↗
8. 10.1126/scitranslmed.aaw332910.1126/scitranslmed.aaw3329 ↗
9. 10.1073/pnas.150540511210.1073/pnas.1505405112 ↗
10. 10.1073/pnas.210259511810.1073/pnas.2102595118 ↗
11. 10.1002/adma.20240460610.1002/adma.202404606 ↗
12. 10.3762/bjnano.12.7710.3762/bjnano.12.77 ↗
13. 10.1007/s13346-021-01076-410.1007/s13346-021-01076-4 ↗
14. 10.3390/mi1211132110.3390/mi12111321 ↗
15. 10.1016/j.addr.2012.04.00510.1016/j.addr.2012.04.005 ↗
16. 10.1021/acsnano.1c0627910.1021/acsnano.1c06279 ↗
17. 10.1016/j.sna.2003.12.02910.1016/j.sna.2003.12.029 ↗
18. 10.1007/s10544-009-9311-y10.1007/s10544-009-9311-y ↗
19. 10.1063/1.512777810.1063/1.5127778 ↗
20. 10.1007/s10544-019-0370-410.1007/s10544-019-0370-4 ↗
21. 10.1039/C5LC00669D10.1039/C5LC00669D ↗
22. 10.3390/app1112532910.3390/app11125329 ↗
23. 10.1016/S0264-410X(03)00377-310.1016/S0264-410X(03)00377-3 ↗
24. 10.1080/21645515.2019.168803210.1080/21645515.2019.1688032 ↗
25. 10.1080/21645515.2023.219578610.1080/21645515.2023.2195786 ↗
26. 10.1016/j.addr.2022.11431310.1016/j.addr.2022.114313 ↗
27. 10.1002/jps.2428310.1002/jps.24283 ↗
28. 10.1007/s10544-016-0113-810.1007/s10544-016-0113-8 ↗
29. 10.1007/s00339-003-2248-810.1007/s00339-003-2248-8 ↗
30. 10.1073/pnas.230364812110.1073/pnas.2303648121 ↗
31. 10.1039/C7LC00644F10.1039/C7LC00644F ↗
32. 10.1126/science.aaa239710.1126/science.aaa2397 ↗
33. 10.1126/sciadv.abq284610.1126/sciadv.abq2846 ↗
34. 10.1126/sciadv.abq391710.1126/sciadv.abq3917 ↗
35. 10.1073/pnas.240538212110.1073/pnas.2405382121 ↗
36. 10.1109/JMEMS.2003.80995910.1109/JMEMS.2003.809959 ↗
37. 10.1007/s00542-009-0883-510.1007/s00542-009-0883-5 ↗
38. 10.1038/s41378-019-0077-y10.1038/s41378-019-0077-y ↗
39. 10.1109/JMEMS.2007.90746110.1109/JMEMS.2007.907461 ↗
40. 10.1016/j.mser.2016.03.00110.1016/j.mser.2016.03.001 ↗
41. 10.1002/EXP.2021017010.1002/EXP.20210170 ↗
42. 10.1007/s11095-020-02844-610.1007/s11095-020-02844-6 ↗
43. 10.1016/j.jphotobiol.2016.03.04710.1016/j.jphotobiol.2016.03.047 ↗
44. 10.1016/j.molimm.2014.10.02310.1016/j.molimm.2014.10.023 ↗
45. 10.1088/0960-1317/20/4/04501110.1088/0960-1317/20/4/045011 ↗
46. 10.1016/j.jmbbm.2014.09.01510.1016/j.jmbbm.2014.09.015 ↗
47. 10.1016/j.jbiomech.2003.12.01010.1016/j.jbiomech.2003.12.010 ↗
48. 10.1097/MD.000000000003316710.1097/MD.0000000000033167 ↗
49. 10.1038/nrendo.2016.8610.1038/nrendo.2016.86 ↗
50. 10.3389/fphar.2022.83827710.3389/fphar.2022.838277 ↗
51. 10.3390/pharmaceutics1211108410.3390/pharmaceutics12111084 ↗
52. 10.1056/NEJMoa131614510.1056/NEJMoa1316145 ↗
53. 10.1016/S0003-2670(00)81494-410.1016/S0003-2670(00)81494-4 ↗
54. 10.3390/molecules2803099210.3390/molecules28030992 ↗
55. 10.3390/pharmaceutics1610134610.3390/pharmaceutics16101346 ↗
56. 10.1371/journal.pntd.000606810.1371/journal.pntd.0006068 ↗
57. 10.1067/mph.2003.4210.1067/mph.2003.42 ↗
58. 10.1001/archfami.3.7.61010.1001/archfami.3.7.610 ↗
59. 10.1615/CritRevTherDrugCarrierSyst.v26.i4.1010.1615/CritRevTherDrugCarrierSyst.v26.i4.10 ↗
60. 10.2147/DHPS.S18447910.2147/DHPS.S184479 ↗
61. 10.3390/vaccines902011710.3390/vaccines9020117 ↗
62. 10.1080/17425247.2019.156962610.1080/17425247.2019.1569626 ↗
63. 10.1093/abt/tbae03010.1093/abt/tbae030 ↗
64. 10.1016/j.vaccine.2014.03.02410.1016/j.vaccine.2014.03.024 ↗
65. 10.1007/s11095-010-0177-810.1007/s11095-010-0177-8 ↗
66. 10.1016/j.jconrel.2012.01.03310.1016/j.jconrel.2012.01.033 ↗